Keywords
CamptothecinMitoxantroneTopoisomeraseTopoisomerase inhibitorBiologySynthetic lethalityDoxorubicinCell cultureHigh-throughput screeningGenotypeCancer researchChemistryMolecular biologyGeneEnzymeBiochemistryGeneticsDNA repairChemotherapy
Affiliated Institutions
Related Publications
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Abstract Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRASG12C inhibitor that ...
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
The mechanisms causing resistance to chemotherapeutic drugs in cancer patients are poorly understood. Recent evidence suggests that different forms of chemotherapy may exert the...
Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Abstract Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. Th...
Publication Info
- Year
- 2003
- Type
- article
- Volume
- 3
- Issue
- 3
- Pages
- 285-296
- Citations
- 1359
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
1359
OpenAlex
Cite This
Sonam Dolma,
Stephen L. Lessnick,
William C. Hahn
et al.
(2003).
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.
Cancer Cell
, 3
(3)
, 285-296.
https://doi.org/10.1016/s1535-6108(03)00050-3
Identifiers
- DOI
- 10.1016/s1535-6108(03)00050-3